SecBot SecBot
Insider Cluster (4 insiders) ·Filed Sep 10, 2026

TWST

Twist Bioscience Corp
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago
Insider cluster: 4 insiders, $0.5M total
Actionable Insight • Neutral

The cluster is too small to warrant a trading signal. Monitor for any upcoming 8-K or earnings release that might have prompted these sales, but the identical pricing and single-day execution strongly suggest a pre-planned 10b5-1 program. No action needed.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$127.22
T+0 close · Sep 10, 2026 · via day close
Latest settled
+25.59%
T+20 · $159.78 · next T+60 in 21d
Vs SPY
+23.73%
α at T+20
Latest observation
+2.36%
T+44 · FF3 residual α
  1. T+0 · Sep 11 $127.22entry
  2. T+1 · 2mo ago +5.92%α +6.37% · $134.75
  3. T+5 · 8w ago +31.26%α +31.60% · $166.99
  4. T+20 · 5w ago +25.59%α +23.73% · $159.78
  5. T+46 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Four Twist Bioscience insiders, including CEO Emily Leproust and CAO Robert Werner, sold a total of $473K in open-market sales on September 8, 2026. The cluster is small relative to the $8.3B market cap (0.006%), and all sales occurred on the same day at the same price, suggesting a routine 10b5-1 plan execution or post-vesting liquidity event rather than a coordinated bearish signal. The sales are immaterial and do not change the company's fundamental outlook.

Key Financial Metrics

Direction
selling
Total Value
$473.0K
Insiders
4

Key Facts

  • CEO Emily Leproust sold 2,302 shares for $282K on Sep 8, 2026
  • CAO Robert Werner sold 238 shares for $29K on Sep 8, 2026
  • Total cluster value of $473K represents 0.006% of $8.3B market cap
  • All four insiders sold on the same day at the same price ($122.62)
  • No insider purchases in the cluster

Financial Impact

Total insider sales of $473K, immaterial relative to $8.3B market cap

dilution

Risk Factors

  • Insider sales could accelerate if the stock continues to rise
  • No purchases to offset the selling signal

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TWST-1789070462870

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026